Ilexgenin A is a pentacyclic triterpenoid, which extracted from Ilex hainanensis Merr. Ilexgenin A can be used for the research of inflammation and cancer[1].
Ilexgenin A (0~100 μM; 24 hours; HT 29 and HCT 116 cells) effectively decreases cell viability in HT 29 and HCT 116 cells[1].Ilexgenin A (12.5~50 μM; 24 hours; HT 29 cells) downregulates the expression of SREBP-1, inhibits the translocation of SREBP-1 to the nucleus and decreases the content of TG[1].Ilexgenin A (12.5~50 μM; HT 29 and HCT 116 cells) induces cell cycle arrest at G1 phase in colon cancer cells[1].Ilexgenin A (12.5~50 μM; 24 hours; HCT 116 cells) modulates lipid metabolism. Ilexgenin A (50 μM; 24 hours; HT 29 and HCT 116 cells) regulates SREBP-1 by inhibiting HIF1α[1].Ilexgenin A inhibits fatty acids synthesis[1].
Ilexgenin A (20 mg/kg) ameliorates the AOM/DSS induced carcinogenesis. Ilexgenin A can regulate lipid metabolism. Ilexgenin A decreases the expression of SREBP-1 and HIF 1α in AOM/DSS mice[1].
[1]. Zhang L, et al. Ilexgenin A prevents early colonic carcinogenesis and reprogramed lipid metabolism through HIF1α/SREBP-1. Phytomedicine. 2019;63:153011.